Tasadenoturev
- Generic Name
- Tasadenoturev
- Drug Type
- Biotech
- CAS Number
- 1448774-00-2
- Unique Ingredient Identifier
- 79ME7DT193
DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas
Phase 1
Completed
- Conditions
- Central Nervous System DiseasesBrain Cancer
- Interventions
- Procedure: Tumor Removal
- First Posted Date
- 2008-12-09
- Last Posted Date
- 2018-07-16
- Lead Sponsor
- DNAtrix, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT00805376
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Safety Study of a Genetically Modified Adenovirus in Ovarian Cancer Patients
Phase 1
Completed
- Conditions
- Ovarian CancerPrimary Peritoneal Cancer
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2011-01-26
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 26
- Registration Number
- NCT00562003
- Locations
- 🇺🇸
UAB Highlands, 1201 11th Ave S, 4th Floor, Gynecologic Oncology, Birmingham, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath